Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) plans to provide an 832.7 million yuan guarantee for its subsidiary Tianjin Zhongxin Medicine, according to a Wednesday filing on the Singapore Exchange.
The guarantee is part of a broader plan to support Tianjin Zhongxin's ongoing operations and facilitate the restructuring of its entrusted loans.
The guarantee will be provided as part of a joint and several liability agreement with Tianjin Pharmaceutical Holding, another shareholder in Tianjin Zhongxin.
It corresponds to Tianjin Pharmaceutical Da Ren Tang's 43.35% stake in Tianjin Pharmaceutical Group Taiping Medicine.
The guarantee requires shareholder approval at an upcoming extraordinary general meeting.
Price (SGD): S$2.05, Change: S$+0.020, Percent Change: +0.99%
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。